Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.37 |
| ▸ | PPARD | Q03181 | 3/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.35 |
| ▸ | ACACB | O00763 | 6/20 | 0.33 |
| ▸ | RXRA | P19793 | 2/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7202310 | 0.88 | HSP90AA1 (0.32) | ACACB | |
| SCHEMBL6426393 | 0.85 | PTGS2 (0.36) | FFAR1ACACB | |
| SCHEMBL5736752 | 0.82 | GABRA1 (0.31) | — | |
| SCHEMBL5735225 | 0.81 | ACACB (0.40) | ACACB | |
| SCHEMBL5734793 | 0.79 | FFAR1 (0.53) | FFAR1CYP26A1ACACB | |
| SCHEMBL5737348 | 0.79 | FFAR1 (0.53) | FFAR1CYP26A1ACACB | |
| SCHEMBL5737048 | 0.77 | FFAR1 (0.43) | FFAR1CYP26A1ACACBRXRARXRB | |
| SCHEMBL5736640 | 0.77 | BACE1 (0.31) | — | |
| SCHEMBL5029906 | 0.75 | CA2 (0.48) | FFAR1NR1H4RXRARXRBRXRG | |
| SCHEMBL5738491 | 0.72 | FFAR1 (0.44) | FFAR1CYP26A1NR1H4ACACBRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1366036-B1 | COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | ALLERGAN INC (US) | 2006-01-11 | — | — | EP | disclosed |
| US-6713647-B2 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2004-03-30 | — | — | US | disclosed |
| US-20030186947-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2003-10-02 | — | — | US | disclosed |
| US-6603019-B2 | Phenylacetic or heteroarylacetic acid derivatives, retinoic acid inducible enzyme, used to treat diseases responsive to retinoids | ALLERGAN, INC. | 2003-08-05 | — | — | US | disclosed |
| EP-1322631-A2 | METHODS OF PROVIDING AND USING COMPOUNDS ( RETINOIDS ) HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | Allergan, Inc. (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030078270-A1 | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2003-04-24 | — | — | US | disclosed |
| US-6531599-B2 | RAI=retinoic acid inducible; for example, 4-((8-cyclopropyl-3,4-dihydro-4,4-dimethylspiro(2H-1-benzopyran-2,1' -cyclopropane)-6-yl) ethynyl)-2-fluoro-benzoic acid; use treating diseases responsive to retinoids | ALLERGAN SALES, INC. | 2003-03-11 | — | — | US | disclosed |
| US-20020193578-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2002-12-19 | — | — | US | disclosed |
| US-6495552-B2 | TREATMENT OR PREVENTION OF THE DISEASES AND CONDITIONS WHICH RESPOND TO TREATMENT BY RETINOIDS AND OR WHICH IN HEALTHY MAMMALS, INCLUDING HUMANS, ARE CONTROLLED BY NATURAL RETINOIC ACID. | ALLERGAN, INC. | 2002-12-17 | — | — | US | disclosed |
| US-20020183285-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2002-12-05 | — | — | US | disclosed |
| US-20020132796-A1 | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2002-09-19 | — | — | US | disclosed |
| US-6399774-B1 | SKIN DISORDERS; CONTROLLING CELL PROLIFERATIVE | ALLERGEN SALES, INC. | 2002-06-04 | — | — | US | disclosed |
| US-6387892-B1 | SKIN DISORDERS; ANTIPROLIFERATIVE AGENT | ALLERGAN SALES, INC. | 2002-05-14 | — | — | US | disclosed |
| US-6387951-B1 | ANTIINFLAMMATORY AGENTS; SKIN DISORDERS | ALLERGAN SALES, INC. | 2002-05-14 | — | — | US | disclosed |
| US-6380256-B1 | FOR THERAPY OF DISEASES RESPONSIVE TO TREATMENT BY RETINOIDS | ALLERGAN SALES, INC. | 2002-04-30 | — | — | US | disclosed |
| WO-2002026727-A2 | METHODS OF PROVIDING AND USING COMPOUNDS (RETINOIDS) HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | ALLERGAN, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
| US-6359135-B1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN SALES, INC. | 2002-03-19 | — | — | US | disclosed |
| US-6313107-B1 | ADMINISTERING TO MAMMAL TO TREAT DISEASES RESPONSIVE TO TREATMENT BY RETINOIDS | ALLERGAN SALES, INC. | 2001-11-06 | — | — | US | disclosed |
| US-6291677-B1 | FOR TREATING SKIN-RELATED DISEASES, INCLUDING, ACTINIC KERATOSES, ARSENIC KERATOSES, INFLAMMATORY AND NON-INFLAMMATORY ACNE, PSORIASIS, ICHTHYOSES AND KERATINIZATION AND HYPERPROLIFERATIVE DISORDERS OF SKIN | ALLERGAN SALES, INC. | 2001-09-18 | — | — | US | disclosed |
| US-6252090-B1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN SALES, INC. | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078270-A1 | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI | CYP26B1, CYP21A2, ALDH1A2 | FFAR1 1743/4885CYP26A1 4/4885PPARD 471/4885 |
| US-20020183285-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | RARA, RARG, RARB | FFAR1 1641/4885CYP26A1 5/4885PPARD 272/4885 |
| US-20020132796-A1 | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI | CYP26B1, CYP21A2, ALDH1A2 | FFAR1 1743/4885CYP26A1 4/4885PPARD 471/4885 |
| US-20030186947-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | RARA, RARB, RARG | FFAR1 1287/4885CYP26A1 6/4885PPARD 231/4885 |
| US-20020193578-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | RARA, RARB, RARG | FFAR1 949/4885CYP26A1 4/4885PPARD 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.